[HTML][HTML] Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated …
IP Naya, L Tombs, DA Lipson, C Compton - Advances in Therapy, 2018 - Springer
Introduction Assessing clinically important measures of disease progression is essential for
evaluating therapeutic effects on disease stability in chronic obstructive pulmonary disease …
evaluating therapeutic effects on disease stability in chronic obstructive pulmonary disease …
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post …
IP Naya, L Tombs, DA Lipson, C Compton - Advances in Therapy, 2018 - europepmc.org
Methods This integrated post hoc analysis of four 12-week, randomized, double-blind trials
(NCT01772134, NCT01772147, NCT01957163, NCT02119286) compared UMEC 62.5 µg …
(NCT01772134, NCT01772147, NCT01957163, NCT02119286) compared UMEC 62.5 µg …
[HTML][HTML] Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated …
IP Naya, L Tombs, DA Lipson, C Compton - Advances in Therapy, 2018 - ncbi.nlm.nih.gov
Results Overall, 1637 patients included in the ITT population received UMEC+ ICS/LABA
(n= 819) or placebo+ ICS/LABA (n= 818). Additional bronchodilation with UMEC reduced …
(n= 819) or placebo+ ICS/LABA (n= 818). Additional bronchodilation with UMEC reduced …
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post …
IP Naya, L Tombs, DA Lipson… - Advances in …, 2018 - pubmed.ncbi.nlm.nih.gov
Introduction Assessing clinically important measures of disease progression is essential for
evaluating therapeutic effects on disease stability in chronic obstructive pulmonary disease …
evaluating therapeutic effects on disease stability in chronic obstructive pulmonary disease …
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post …
IP Naya, L Tombs, DA Lipson, C Compton - Advances in Therapy, 2018 - hero.epa.gov
Introduction: Assessing clinically important measures of disease progression is essential for
evaluating therapeutic effects on disease stability in chronic obstructive pulmonary disease …
evaluating therapeutic effects on disease stability in chronic obstructive pulmonary disease …